-
Sector Analysis
NewDiabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Report Overview Diabetic Nephropathy (DN) is glomerular sclerosis and fibrosis caused by the metabolic and hemodynamic changes of diabetes mellitus (DM). It manifests as slowly progressive albuminuria with worsening hypertension and renal insufficiency. DN is the most common cause of nephrotic syndrome in adults and is also the most common cause of end-stage renal disease (ESRD) in the US, accounting for up to 80% of cases. Renal failure is particularly common in certain...
-
Product Insights
Diabetic Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Diabetic Macular Edema Clinical Trials Market Report Overview The Diabetic Macular Edema Clinical Trials market research report provides an overview of Diabetic Macular Edema Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Macular Edema. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Sector Analysis
Painful Diabetic Neuropathy Epidemiology Analysis and Forecast to 2031
Painful Diabetic Neuropathy Market Report Overview The total prevalent cases of Painful Diabetic Neuropathy (PDN) were 7,472,695 cases in the seven major markets (7MM) in 2021 and are expected to achieve an AGR of more than 1% during 2021-2031. Diabetic neuropathy refers to a variety of syndromes that differ in clinical course, distribution, and fiber involvement. Symptoms of diabetic neuropathy vary widely from patient to patient, and some patients with diabetic neuropathy have no symptoms. The PDN market research report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.